<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="160212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012999</url>
  </required_header>
  <id_info>
    <org_study_id>32225</org_study_id>
    <nct_id>NCT01012999</nct_id>
  </id_info>
  <brief_title>A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain</brief_title>
  <official_title>Pain Control and Patient Satisfaction: a Dosing Study to Determine a Safe and Effective Dose of Intra-nasal Sufentanil to Treat Emergency Department Patients With Moderate to Severe Pain Due to Extremity Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the appropriate dose and effectiveness of
      intra-nasal administration of a potent narcotic, sufentanil, for the treatment of moderate
      to severe pain due to broken bone(s) in the arm or leg.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling patients
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant pain relief</measure>
    <time_frame>Within 30 minutes of drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of intra-nasal sufentanil</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pain</condition>
  <condition>Opiate</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>Intra-nasal delivery, dosing range 0.5-1.0 mcg/kg, administered once at the beginning of the 30 minute study period</description>
    <other_name>Sufenta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 yo or older;

          -  isolated traumatic injury to upper or lower extremity;

          -  alert and oriented to name, date, place; patient has a numeric pain score of 5 or
             higher;

          -  speaks English as their primary language;

          -  female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal
             ligation)

        Exclusion Criteria:

          -  injury isolated to a finger or toe;

          -  previous nasal or sinus surgery; chronic nasal problem;

          -  acute nasal problem (ie epistaxis, URI, sinusitis);

          -  pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of
             analgesic abuse or dependency;

          -  presence of other painful injuries; systolic BP less than 100 mm Hg;

          -  patient seems or is confused or has a head injury; room air oxygenation less than
             95%;

          -  patient has COPD, severe asthma, oxygen-dependent pulmonary disease;

          -  impaired hepatic or renal function (obtained clinically or by history);

          -  weight more than 230 lbs (100 kg);

          -  alcohol or drug intoxication (per patient admission or clinical assessment of
             physician);

          -  elderly (&gt; 70 years)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Stephen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 28, 2011</lastchanged_date>
  <firstreceived_date>November 11, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Robert Stephen, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>acute pain, intranasal, sufentanil,</keyword>
  <keyword>Acute pain control with an intranasal opiate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
